Lamellar Biomedical is an innovative biotechnology company. Along with our in-house research and development team, we are collaborating with world renowned institutions and universities. We believe that our LAMELLASOME™ technology will play a key role in realising the potential of many of the nucleic acids in development, including microRNAs, siRNAs, mRNAs and plasmid DNA, potentially revolutionising the treatment of numerous rare and intractable diseases.
Since 2012, the Company has invested heavily in developing in-house R&D capabilities to advance pioneering research in nucleic acid transfer. In February 2018, the Company moved into bespoke laboratories and offices, advancing the testing of active agent LAMELLASOME™ products (including nucleic acids) in in vitro cell models, CF infection models and significantly extending our formulation and processing capabilities.
Lamellar was founded in 2007 and is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities, such as the University of Edinburgh, the University of Strathclyde’s Institute of Pharmacy and Biomedical Sciences, and the University of Freiburg’s Institute of Pharmaceutical Science.
Lamellar’s patent portfolio has recently expanded to include a promising new LAMELLASOME™ Nucleic Acid Transfer technology and some key products that demonstrate the potential of the technology. For more information, please contact us.
Collaboration & partnerships
Lamellar Biomedical is a member of the Scottish Life Sciences Association (SLA).
We have an agreement with the Edinburgh Complex Fluids Partnership to advance research into the biophysical properties of LAMELLASOME™.
We have also recently entered into partnerships with the University of Edinburgh and the University of Strathclyde to further optimise our LAMELLASOME™ platform and its product manufacturing processes.
Lamellar also have a collaboration with the Institute of Pharmaceutical Science group at the University of Freiburg in Germany. This collaboration supports our LAMELLASOME™ Nucleic Acid delivery platform focussing on aspects of efficient and functional nucleic acid delivery.
Grants & awards
The scientific and commercial potential of the LAMELLASOME™ technology has been recognised by the award of two concurrent Knowledge Transfer Partnerships (KTP). The first one was initiated by Lamellar and the Edinburgh Complex Fluids Partnership of Edinburgh University to develop LAMELLASOME™ properties for use in the treatment of CF.
Together with Professor Perrie of Strathclyde University, an internationally recognised professor in drug delivery, we were awarded our second Innovate UK KTP for the process optimisation and characterisation of LAMELLASOME™ formulations.
Lamellar won an MRS PhD studentship with the Roslin Institute for the study of LAMELLASOME™ as an antifibrotic agent.
The Company has also been successful in attracting major grants to support our in-house research including SMART Scotland, EPSRC IAAs, MRS, SULSA, KTP and BBSRC iCase grants.